SES
3.11.2020 08:52:12 CET | Business Wire | Press release
SES today announced Gilat and ST Engineering iDirect as its latest technology partners who will be developing the core infrastructure modem platforms for O3b mPOWER , SES’s ground-breaking non-geostationary-satellite orbit (NGSO) communications system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102006117/en/
Gilat and ST Engineering iDirect were selected based on their next-generation modem technologies. Featuring open architectures with a path to full virtualisation, the modems will interface with SES’s differentiated Adaptive Resource Control (ARC) capability and leverage SES’s use of the Open Networking Automation Platform (ONAP) standard. The combination of this and other technologies will give SES the ability to dynamically control and optimise the entire O3b mPOWER system across space and ground infrastructure, enabling the efficient delivery of low-latency and high-throughput satellite-based data services that can be truly customised to fit specific connectivity requirements on land, at sea or in the air anywhere in the world.
O3b mPOWER is SES’s next-generation medium Earth orbit (MEO) communications system. It is currently under construction and on track for launch in 2021. The high-throughput satellites, as well as automated and intelligence-powered ground infrastructure, will deliver low-latency managed services from hundreds of Mbps up to multiple Gbps.
"We are honoured to have been selected by SES, our long-time strategic partner, to provide our next-generation baseband platform for O3b mPOWER. Gilat's innovative ground segment significantly reduces cost-per-bit, delivers a step-change in modem performance, and further integrates with and optimises SES ground and space service delivery," said Ron Levin Vice President Mobility and Global Accounts at Gilat. "Throughout the last year, we have been working closely with SES to develop the platform for O3b mPOWER with the joint goal of bringing to market unparalleled customer experience in all target verticals.”
“We are at the beginning of a new future for our industry. To be selected for O3b mPOWER is a tremendous validation of ST Engineering iDirect's technology vision and proves that ground infrastructure will play a pivotal role in SES’s ambitious goal to transform satellite service delivery,” said Frederik Simoens, CTO, ST Engineering iDirect. “O3b mPOWER is at the forefront of a significant movement to drive a standards-based, virtualised network approach where ground is in lockstep with space. Through our partnership, we will greatly expand the possibilities for global connectivity.”
“The basis of our O3b mPOWER communications system is defined and advanced by a diverse and robust partner ecosystem. As an industry, we are able to embrace the vision of open networking and seamless satellite services because of like-minded partners such as Gilat and ST Engineering iDirect who understand the step-change in system flexibility and capacity that O3b mPOWER will deliver,” said Stewart Sanders, SES’s Executive Vice President of Technology and O3b mPOWER programme manager. “We have first-hand experience over many years of working with both Gilat and ST Engineering iDirect and have always been impressed with their work as well as what their technologies can provide. Hence, we have full confidence in selecting these two outstanding companies as trusted partners for O3b mPOWER and to deliver a key part of our infrastructure supporting an unparalleled customer experience.”
Focused on making satellites a seamless part of global network solutions, SES has been steadily expanding its O3b mPOWER partner ecosystem. In addition to Gilat and ST Engineering iDirect, SES has also announced O3b mPOWER partnerships with SpaceX for launches, ALCAN, Isotropic Systems and Viasat for customer edge terminals, Amdocs for NFV technology, Kythera Space Solutions for the ARC software, Microsoft for gateways , and IBM and Microsoft for cloud connectivity.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102006117/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom